Still life of Wegovy with a weight scale.

(Michael Siluk/Getty Images)

Hims & Hers surges after announcing partnership with Ozempic maker Novo Nordisk

The partnership will start off by giving Hims & Hers users direct access to NovoCare, the drugmaker’s direct-to-consumer platform.

J. Edward Moreno

4/29/25 7:05AM

Hims & Hers shot up 30% in premarket trading after it announced a collaboration with Novo Nordisk, the drugmaker that manufactures Ozempic and Wegovy.

In a Tuesday morning announcement, the telehealth company said that “as a first step,” its patients would be able to access NovoCare, Novo’s direct-to-consumer platform, through Hims & Hers. The two companies are “developing a roadmap that combines Novo Nordisk’s innovative medications with Hims & Hers’ ability to deliver access to quality care at scale,” Dave Moore, head of Novo’s US operations, said in a statement.

Hims has been selling copycat versions of Novo’s weight-loss drugs for about a year while they were in a shortage, and its ability to continue doing so was going to be significantly limited after May 22. NovoCare comes at a flat price of $599 for a month’s supply, compared to the roughly $200 a month Hims charges for compounded semaglutide, the active ingredient in Ozempic and Wegovy.

Investors have been eager for a sign that Hims would be able to continue selling blockbuster weight-loss drugs that have taken the country by storm in recent years. Earlier this month, the company’s stock jumped after investors misinterpreted an announcement from the company as a partnership with Eli Lilly, but those gains quickly faded.

Lilly and Novo have both launched ad campaigns questioning the safety of compounded weight-loss injections, like those sold by Hims. Last week, Lilly sued a group of telehealth companies selling “personalized” copies of its weight-loss drugs.

Hims sells only compounded versions of Novo’s drugs and has previously suggested that it would also continue selling personalized versions after May 22. Hims CEO Andrew Dudum told Sherwood News in an interview last month that the need to adjust doses of semaglutide is “extremely high.”

A spokesperson for Hims told Sherwood on Tuesday that it plans to “still offer access to personalized compounded treatments in cases where it’s clinically appropriate.”

Ro, one of Hims’ top competitors, also announced a nearly identical partnership with Novo on Tuesday — though users on Ro can get a month’s supply for $499, compared to $599 through Hims. Ro already has a partnership with Lilly to offer vials of Zepbound on its platform. Dudum has said previous efforts to collaborate with Novo and Lilly have not worked out because of the necessary scale.

While Tuesday’s announcement doesn’t necessarily create new options for consumers, it does seem to reduce the looming risk that Novo may sue Hims, a risk analysts have consistently been pricing in.

Luke Kawa50m

POET Technologies tumbles after announcing $150 million direct share offering

POET Technologies is tumbling in early trading Thursday after the optical communications company announced that it’s raising $150 million through the sale of about 20.7 million shares in a registered direct offering.

It’s an opportunity for management to cash in on the stock’s more than 30% rally year to date (as of Wednesday’s close).

“With a substantial base of cash, we plan to accelerate our pursuit of targeted acquisitions, add to our capabilities and talent base, vertically integrate our products with differentiated components, and expand operations to pursue revenue opportunities across the board, in order to bring long-term value to shareholders,” Executive Chairman and CEO Dr. Suresh Venkatesan said.

POET’s last offering came in late October, after which shares nearly halved in less than a month amid a broad drawdown in speculative, volatile stocks beloved by retail traders.

Luke Kawa2h

Oracle gains amid report that the TikTok deal is poised to close this week

Oracle is gaining in premarket trading as Semafor reports that China and the US have signed off on the sale of TikTok’s US operations to a consortium in which the software giant is one of the three leading investors.

The transaction is poised to close this week, per the report, citing people familiar with the situation.

In mid-December, Oracle booked a huge gain after the CEO of TikTok owner ByteDance indicated that he’d signed contracts with Oracle and the other major investors leading this consortium, private equity firm Silver Lake and Abu Dhabi-backed tech investment company MGX.

If, as previous reporting suggested, the transaction values TikTok’s US operations at about $14 billion, that would mark a fairly low price tag for a lot of eyeballs and ad dollars. This pact will also afford Oracle’s cloud business an opportunity to deepen its preexisting relationship with TikTok.

J. Edward Moreno2h

Abbott slumps after reporting sales miss, disappointing Q1 guidance

Abbott Laboratories fell in premarket trading after it reported fourth-quarter sales that missed Wall Street estimates and gave disappointing guidance for the current quarter.

The company said it expects to report first-quarter adjusted earnings per share of between $1.12 and $1.18, below the $1.20 analysts polled by FactSet were expecting. For the full year, it expects to report adjusted earnings per share of $5.55 to $5.80, in line with the $5.67 the Street is penciling in.

Abbott also reported $11.5 billion in sales for the fourth quarter, less than the analyst consensus of $11.8 billion. The sales miss was driven by lower-than-expected sales of its medical devices, its largest segment. Its profits for the quarter hit $1.50 per share, right in line with expectations.

The stock fell more than 5% in premarket trading on Thursday.

GE Aerospace posts better-than-expected Q4 results and surprisingly strong full-year profit guidance

GE Aerospace had a strong 2025, rising roughly 85% to outpace both the S&P 500 and industry benchmarks.

Matt Phillips3h

Hyunsoo Rim3h

Goldman hikes year-end gold price forecast to $5,400 per ounce as private investors and central banks compete for the shiny stuff

Goldman Sachs has raised its December 2026 gold price forecast to $5,400 per ounce, up from the previous $4,900 target, citing strong demand from private sector investors using gold as a hedge against global policy risks, according to a note released late Tuesday.

The revised price target reflects a 17% increase from January’s month-to-date average price, with continued central bank buying as the biggest driver of the forecast (accounting for 14 percentage points of the expected appreciation), while ETF inflows add another 3 pp — supported by an assumed Fed rate cut this year.

Central banks have been on a gold-buying spree since 2022, after the freezing of Russia’s foreign reserves, helping push prices up 15% in 2023 and 26% in 2024. But Goldman analysts noted that the rally accelerated in 2025 as competition between central banks and private investors for the limited bullion intensified — driving prices up another 67% last year, with recent tensions over Greenland only adding to the momentum.

That private sector demand now extends well beyond ETF inflows. Goldman said buying is increasingly coming from a new class of investors seeking protection against macro policy risk and currency “debasement,” including purchases from high-net-worth families and call option buying — flows that are “hard to track” but have become a “significant incremental source of demand.”

Goldman assumed these macro-related “sticky” hedges will persist through 2026 — unlike those tied to the 2024 US election, which unwound quickly once the outcome was clear.